Poster Abstracts • OFID 2018:5 (Suppl 1) • S743 and the evidence to evaluate it is limited. Dynamic transmission model outcomes of impact and cost-effectiveness of universal varicella vaccination (UVV) are sensitive to EB characterization and assumptions, occasionally leading to conclusions that UVV programs may not be cost-effective and could lead to temporary increases in HZ incidence. The goal of this study was to use data from 20 years of UVV in the United States from 1996 to 2016 to evaluate whether the hypothesized increases in HZ incidence have been realized.
Background. There are more than 300,000 cases of varicella annually; nonimmune individuals exposed to varicella-zoster (VZ) virus have a high likelihood of developing varicella. VZ immune globulin (VARIZIG ® ) is used for postexposure prophylaxis to prevent or attenuate VZ infection in high-risk individuals. We assessed varicella incidence and severity in high-risk subjects after administration of VZ immune globulin.
Methods. This open-label expanded-access program provided VZ immune globulin to physician-identified, high-risk subjects exposed to varicella. Subjects included immunocompromised children/adults, infants (including preterm infants, newborns whose mothers had VZ infection <5 days before or <2 days after delivery, and infants <1 year of age), and pregnant women. VZ immune globulin (125 IU/10 kg [up to 625 IU]) was administered intramuscularly, ideally ≤96 hours, but up to 10 days, postexposure. Incidence of varicella rash and severity (>100 pox, pneumonia, encephalitis) were assessed up to 42 days after administration.
Results. The efficacy population (n = 505) included 263 immunocompromised subjects (32 adults, 231 pediatric), 137 pregnant women, and 105 infants. More than 97% of exposures fit the CDC definition. Varicella incidence was low in immunocompromised subjects (4.5%, n = 12/269), pregnant women (7.3%, n = 10/137), and infants (11.4%, n = 12/105) and was similar when comparing administration ≤ 96 hours vs. up to 10 days postexposure (6.2% vs. 9.4%, respectively). Of 34 subjects with varicella, 54% were exposed in the household; 5 were considered severe. Common adverse events were pyrexia (4%), neutropenia (3%), and headache (3%). There were no product-related deaths and only 1 serious adverse event (serum sickness) considered probably related to VZ immune globulin.
Conclusion. Postexposure administration of VZ immune globulin resulted in low rates of varicella in high-risk subjects, regardless of administration timing within 10 days postexposure. VZ immune globulin-which is FDA-approved, recommended by the CDC, and widely available-was well tolerated and safe in high-risk subjects.
Disclosures Methods. An extensive literature search was performed in Embase and Medline for the period January 2007 to January 2018 to identify peer-reviewed, original, English study manuscripts reporting the results of observational studies of ZVL VE. In all studies, HZ cases were identified from HZ diagnosis codes, with only two studies also requiring HZ-specific antiviral use. For PHN, different case definitions were used across studies, usually without validation from medical chart review.
Results. Seven original effectiveness studies were identified (5 from the United States and 1 each from the UK and Canada) that assessed HZ effectiveness in the general population. Five of these studies also assessed PHN effectiveness. Vaccine effectiveness to prevent HZ was similar across studies in the early years following vaccination, but tended to diverge in the later years (overall VE against HZ ranged from 33% to 62%, clustering around ~50% across studies providing this information). Overall VE against PHN ranged from 55% to 88%, clustering around ~65%.
Conclusion. Real-world observational studies assessing the effectiveness of ZVL in preventing HZ and PHN in the general population reported generally similar results. Differences in VE estimates across studies were likely driven by differences in study design and methods, including sample size and age of study population, HZ and PHN case definition, duration of follow-up, and methods of covariate selection, definition and adjustment. We are currently conducting a meta-analysis to identify and quantify the potential heterogeneity across studies and calculate summary VE estimates. Background. Zostavax™, a live zoster vaccine licensed as 1 dose, is indicated in the United States for the prevention of herpes zoster (HZ) in people 50 years or older. Real-world vaccine effectiveness (VE) and duration of protection are being evaluated in an ongoing study. Compared with randomized clinical trials, this large observational study includes a more diverse population and offers a unique opportunity to assess VE across sex and race/ethnic groups.
Methods. Kaiser Permanente Northern California members enter the ongoing cohort study when age-eligible for zoster vaccine, starting in 2007. Incident HZ is defined as a new HZ diagnosis accompanied by an antiviral prescription or a positive varicella-zoster virus test, with no HZ diagnosis in the preceding 12 months. VE by sex S744 • OFID 2018:5 (Suppl 1) • Poster Abstracts and race/ethnicity was estimated using Cox regression models controlling for age and adjusting for healthcare use, comorbidities and immunocompromise status.
Results. During 2007 During -2014 ,720 individuals entered the study, including 724,283 (53.4%) females. Among the unvaccinated, the incidence rate of HZ was 7.5 and 10.2 cases per 1,000 person-years (PY) among males and females, respectively. VE was 51.6% [95% CI: 49.2, 53.9] in males and 47. 7% [45.8, 49.6] 
